Hematologic Malignancies

AYA Tumor Board

Questions discussed in this category

What is your first line of therapy for refractory Hodgkin lymphoma in an AYA patient?

1 Answer available

What is the preferred regimen for AYA patients with T-Cell Lymphoblastic Lymphoma?

1 Answer available

Should a teenager diagnosed with CML in blast crisis go to transplant once MRD is negative?

2 Answers available

Would you recommend hematopoietic stem cell transplant for AYAs with Ph-like ALL?

1 Answer available

What is the preferred treatment approach for an AYA patient with intermediate to high risk Hodgkin lymphoma: The pediatric approach (ABVE-PC +/- radiation) or the adult approach (ABVD with possible escalation to BEACOPP)?

1 Answer available

What is your approach for salvage therapy in a patient with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma that has received a Rituximab-containing upfront regimen?

1 Answer available

Is dexrazoxane recommended for cardioprotection in AYA patients with Hodgkin lymphoma who are receiving anthracyclines as part of their upfront therapy?

3 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20

Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.

J Clin Oncol, 2020 Apr 28

Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Blood, 2009-09-03

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

J Clin Oncol, 2019 Oct 14

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.

N. Engl. J. Med., 2018-01-25

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Biol. Blood Marrow Transplant., 2019 Aug 22

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.

Bone Marrow Transplant, 2018 Nov 01

Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Biol Blood Marrow Transplant, 2019 Aug 21

Hematopoietic Cell Transplant Consideration for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia Patients.

J Clin Oncol,

Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.

Biol Blood Marrow Transplant, 2019 Jul 01

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party.

Ann Hematol, 2015 Mar 27

Management of chronic myeloid leukemia in blast crisis.

Leukemia, 2008-12

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

British journal of haematology, 2014-06

F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.

International journal of radiation oncology, biology, physics, 2019-06-01

Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.

Blood, 2018-07-05

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Blood,

Getting to transplant in Hodgkin lymphoma: BVB.

Blood,

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.

J Clin Oncol, 2021 Jun 25

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.

Hematologic Malignancies

AYA Tumor Board

Questions discussed in this category

Papers discussed in this category

Related Topics in Hematologic Malignancies